McKesson Corp.

McKesson provides pharmaceuticals and medical supplies and services to its customers. The company's segments include: U.S. Pharmaceutical and Specialty Solutions, which provides distribution and logistics services for branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs and other healthcare-related products to customers; European Pharmaceutical Solutions, which provides distribution and services to wholesale, institutional and retail customers in European countries where it owns, partners or franchises with retail pharmacies; and Medical-Surgical Solutions, which delivers medical-supply distribution, logistics, biomedical and other services to healthcare providers.
  • TickerMCK
  • ISINUS58155Q1031
  • ExchangeNew York Stock Exchange
  • SectorFood & Drug Retailers
  • CountryUnited States

Moody's announces completion of a periodic review of ratings of McKesson Corporation

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of McKesson Corporation. Global Credit Research- 06 Apr 2020. New York, April 06, 2020-- Moody's Investors Service has completed a periodic review of the ratings of McKesson Corporation and other ratings that are associated with the same analytical unit.

With a more favourable environment, MCKESSON CORPORATION improves to Slightly Positive

MCKESSON CORPORATION (US), a company active in the Drug Retailers industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date March 10, 2020, the closing price was USD 138.00 and its potential was estimated at USD 178.65.

McKesson Corporation: Update to credit analysis following ratings affirmation

McKesson will continue to be an industry leader, with significant scale and moderate financial leverage as it navigates growing uncertainties related to its opioid-related liability.

Moody's affirms McKesson's Baa2 senior unsecured rating; outlook stable

Rating Action: Moody's affirms McKesson's Baa2 senior unsecured rating; outlook stable. Global Credit Research- 17 Jan 2020. New York, January 17, 2020-- Moody's Investors Service affirmed McKesson Corporation's Baa2 senior unsecured rating and Prime-2 senior unsecured commercial paper rating.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • John Betz

Vermilion Int'l Compass: Global Equity Strategy

Big-picture technicals offer a compelling outlook for equities -- in the long-run. Despite arguably stretched trends, especially in the U.S. and EM, one indicator in particular keeps us optimistic: monthly charts. What is likely the least-used timeframe, monthly charts (> 20 years) offer the most clarity. And what's clear right now is: (1) Europe is on the doorstep of breaking above secular resistance; (2) Japan is breaking out above secular resistance; (3) and EM already has. Speaking of EM, we view this as the place to be, or overweight, in 2018. The EM/EAFE's 20-year chart (below) reveals ...

1 director sold

A director at Mckesson Corp sold 1,350 shares at 128.690USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board ...

MarketLine Department

Medline Industries, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Medline Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Medline Industries, Inc. (Medline or 'the company') is a privately-held provider of healthcare supplies and equipment. The company manufactures and distributes medical and surgical products to healthcare institutions, home health, hospice, physician office, assisted living, managed ...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior